IHMA Completes the Globalization of its Two Laboratories with the Recent College of American Pathologists (CAP) Accreditation of IHMA Europe
Enhancing Support for Clinical Trials in Anti-Infective Drug Development and Global Surveillance Studies
SCHAUMBURG, Ill., March 06, 2018 (GLOBE NEWSWIRE) -- On 14th October 2017 IHMA Europe Sàrl, located in Monthey, Valais, Switzerland, was awarded accreditation by the College of American Pathologists (CAP). With this important development both IHMA facilities, located in the US and Europe, are now CAP accredited. These accreditations further advance IHMA's global commitment to the highest quality of central laboratory clinical microbiology services that are essential for providing timely and accurate results in support of anti-infective clinical trials and global surveillance studies on a worldwide basis.
IHMA Europe's Chief Executive Officer, Dr Stephen Hawser said, "CAP accreditation is a truly positive acknowledgement of the high quality of services IHMA Europe provides to the pharmaceutical and biotechnology industries to support antimicrobial development".
Jack Johnson, President and CEO of IHMA said, "It has been our desire to globalize the two laboratories to ensure our pharmaceutical and biotechnology clients, that all services provided by IHMA and IHMA Europe are exactly the same and meet the highest standards and quality found in our industry. The CAP accreditation provides that platform."
About IHMA, Inc. and IHMA Europe S à rl
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA's services can be customized to best align with its clients' unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.
For more information, visit the IHMA website at: www.ihma.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IHMA Inc via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems21.3.2018 15:00 | Pressmeddelande
Inclusion marks the first time 3Gtms has been named to the Magic Quadrant SHELTON, Conn., March 21, 2018 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software, today announced it has been positioned by Gartner, Inc. in the Niche Players quadrant of the report, Magic Quadrant for Transportation Management Systems*. This is the first time 3Gtms has been positioned within the Magic Quadrant. According to the report, the research "focuses on holistic multimodal domestic TMSs for use by shippers (such as manufacturers, retailers, distributors and wholesalers) or non-asset-based, third-party logistics (3PL) organizations." Key criteria for the 2018 Magic Quadrant included: The breadth of the TMS; depth of the TMS; usability and adaptability; global go-to market strategy and offering; partner ecosystem; vision, thought leadership, roadmap, and track record; and a compelling SCE convergence strategy. The full report is available at no charge at the 3Gt
Further UHNWI Investment To Support FinTech Entrepreneur Zichain's Growth and Innovation21.3.2018 14:46 | Pressmeddelande
Zichain / Further UHNWI Investment To Support FinTech Entrepreneur Zichain's Growth and Innovation . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. ZURICH, Switzerland, March 21, 2018 (GLOBE NEWSWIRE) -- Zichain, a Switzerland-based digital asset management company, is pleased to announce that it has secured an USD 1.2m investment from a syndicate of UHNW Hong-Kong based investors, supporting further development of its unique cryptocurrency products. The deal was confirmed while the Company was participating at the Goldman Sachs 2018 Disruptive Technology Symposium, held in London on 20-21 March. As a pioneer of the cryptocurrency index industry, Zichain has enjoyed exponential growth with the Company now taking a leading role in the creation of digital asset management industry. Zichain is focused on the development of three key products: Blockchain Asset Management Platform (BAMP), a unique and convenien
Addivant Announces Price Increases on Hindered Amine Light Stablizers21.3.2018 14:38 | Pressmeddelande
DANBURY, Conn., March 21, 2018 (GLOBE NEWSWIRE) -- Effective immediately or as contract terms allow, Addivant(TM), a global leader in polymer additives, is increasing the price of Hindered Amine Light Stabilizers by up to 15%. The adjustment is driven by raw material cost increases and market conditions. About Addivant(TM) Addivant(TM) is an innovator in the field of polymer additives, developing customized solutions that provide customers enhanced application performance, safe handling, and reduction in cost of use. The company is recognized industry-wide for its extensive portfolio of specialty additives including antioxidants, light stabilizers, rubber additives, polymer modifiers, metal deactivators, polymerization inhibitors and intermediates. Addivant is an international company, with 11 plants in five regions as well as research, manufacturing and sales facilities around the globe. Addivant maintains its global headquarters in Connecticut, USA with regional headquarters in: Al J
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour21.3.2018 14:17 | Pressmeddelande
Customers to join the most prestigious worldwide polo tournament LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, will be offering customers the opportunity to enrich their passion for polo as the company partners with British Polo Day for the 2018 worldwide tournament, following a successful inaugurate partnership last year. The sport is a key interest for many of VistaJet's customers, both as spectators and riders, and is in line with 39% of the world's animal-loving Ultra High Net Worth population having a passion for horses*. VistaJet continuously develops and offers exceptional experiences for its customers inspired by their true passions, including art, sport and travel, across all cultures worldwide. Its global partnership with British Polo Day will offer customers an exclusive opportunity to enjoy one of their most cherished interests by watching some of the sport's top players, including the world's number one player Adol
Immunicum AB: Invitation to Investor Events21.3.2018 14:00 | Pressmeddelande
Press Release 21 March 2018 Immunicum AB: Invitation to Investor Events Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that the Company will host two investor events in April. At both events, Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session. Stockholm Date: Wednesday, April 11, 2018 Time: 18:00 - 20:00 CET Location: Citykonferensen Ingenjörshuset Room: Styrelserummet Malmskillnadsgatan 46 111 84 Stockholm Gothenburg Date: Wednesday, April 18, 2018 Time: 18:00 - 20:00 CET Location: First Hotel G Restaurant Orkidé Nils Ericsonplatsen 4 411 03 Gothenburg To register to attend the events, please send an email to email@example.com with your full name and the selected location (Stockholm or Gothenburg). For more information, please contact:
Immunicum AB: Inbjudan till investerarkvällar21.3.2018 14:00 | Pressmeddelande
Pressmeddelande 21 mars 2018 Immunicum AB: Inbjudan till investerarkvällar Immunicum AB (IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelade idag att bolaget kommer att ordna två investerarkvällar i april. Vid båda tillfällena kommer Immunicums VD Carlos de Sousa att hålla en presentation av det dagsaktuella läget i bolaget, och han och övriga medlemmar i ledningen är tillgängliga för att svara på frågor. Stockholm Datum: onsdag, 11 april 2018 Tid: 18:00-20:00 CET Plats: Citykonferensen Ingenjörshuset Sal: Styrelserummet Malmskillnadsgatan 46 111 84 Stockholm Göteborg Datum: onsdag, 18 april 2018 Tid: 18:00-20:00 CET Plats: First Hotel G Sal: Orkidé i restaurangen Nils Ericsonplatsen 4 411 03 Göteborg För att delta i investerarkvällarna, skicka ett mejl till firstname.lastname@example.org med ditt fullständiga namn och orten där du vill delta (Stockholm eller Göteborg). För ytterligare information kontakta: Carlos de So
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum